Grab MYOV Stock While It's on Sale, Says Goldman

Short interest, on the other hand, has reached an all-time high

Digital Content Manager
Aug 28, 2019 at 9:35 AM
facebook twitter linkedin

The shares of U.K.-based biotech Myovant Sciences Ltd (NYSE:MYOV) are popping this morning on a bull note from Goldman Sachs. The analyst initiated coverage on the stock with a "buy" rating, and a $20 price target -- more than double last night's close of $7.86. Goldman said the stock's recent dip provides a good entry point for buyers, and sees promise for the drugmaker's relugolix product. MYOV is up 6% at $8.33 in response, set for its highest close since July. 

Goldman's optimism is nothing new among the brokerage bunch. The security's consensus 12-month price target of $26 represents a level MYOV hasn't traversed in over a year. Plus, all seven analysts in coverage, prior to today, called the pharma stock a "strong buy."

This analyst sentiment seems to be a real case of rooting for the underdog, considering MYOV's 50% year-to-date deficit, and last month's all-time low of $6.60. Since this bottom, however, the equity has managed to tack on 26.2%, with the 30-day moving average acting as support of late. Plus, MYOV is set to finish atop its 60-day moving average for the first time in four months. 

Short sellers have remained interested, though, judging by the 40.2% surge in these pessimistic positions during the last two reporting periods. The 3.02 million shares sold short is a record high for MYOV, and represents 9.7% of the stock's float. What's more, it would take nine days to cover all these bearish bets at the security's average pace of trading.




Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Schaeffer's Daily Bulletin Offer


Special Offers from Schaeffer's Trading Partners